Skip to main navigation
Barinthus Biotherapeutics logo
Top Navigation
  • Home
  • About Us
    • Overview
    • Our Team
    • A Name with Purpose
  • Technology
    • Overview
    • Viral Vector Platforms
    • Synthetic Platforms
  • Pipeline
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Partnerships
    • Overview
    • Infectious Diseases
    • Autoimmunity
    • Cancer
  • Investors
    • Overview
    • News & Filings
    • Events & Presentations
    • Stock Information
    • Corporate Governance
    • Investor FAQs
    • Contact IR
  • Careers
    • Overview
    • Working Here
    • Diversity & Inclusion
    • Our Values
    • Recruitment Companies
  • Contact
    • Overview
    • Patient Enquiries
Select Page

SEC Filing Details

Toolkit
  • Subscribe
  • RSS Feeds
  • Contact IR
  • Presentations
Sub Nav News & Filings
Press Releases
SEC Filings
Annual Reports and AGM
Quarterly Results
SEC Filing Details

SEC Filing

Document Details

Form
ARS
Filing Date
Jun 10, 2026
Document Date
Dec 31, 2025
Form Description
An annual report to security holders
Filing Group
Annual Filings
Company
Barinthus Biotherapeutics
Issuer
BARINTHUS BIOTHERAPEUTICS PLC.

SEC Filing

Filing Formats

View HTML
Download PDF
Download DOC

Barinthus Biotherapeutics plc

Unit 6-10
Zeus Building
Rutherford Avenue
Harwell OX11 0DF
United Kingdom

T: +44 (0)1865 818808

Footer Links
Home
About
Sitemap
Privacy Policy
Privacy Notice
Careers
Contact
Barinthus Biotherapeutics logo
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of antigen-specific immunotherapeutics that induce T cells to treat chronic viral infections, autoimmune diseases, and cancer.
© Barinthus Biotherapeutics 2026 All rights reserved.
Social Media Links
  • Follow us on X
  • Follow us on LinkedIn